UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(X)	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934		
	For Quarterly Period Ended J	ANUARY 31, 2000	
()	Transition Report Pursuant t Exchange Act of 1934	o Section 13 or 15(d) o	f the Securities
	For the transition period fr	om to	
Commiss	ion File Number 1-8597		
	THE COOPER	COMPANIES, INC.	
	(Exact name of registran		harter)
	Delaware		94-2657368
(State	or other jurisdiction of oration or organization)		(I.R.S. Employer Identification No.)
	6140 Stoneridge Mall Road,	Suite 590, Pleasanton,	CA 94588
	(Address of principal exec	utive offices) (Zip Code)
Registra	ant's telephone number, includ	ing area code (925) 460	-3600
to be fi the pred required	e by check mark whether the re iled by Section 13 or 15(d) of ceding 12 months (or for such d to file such reports), and (ments for the past 90 days.	the Securities Exchang shorter period that the	e Act of 1934 during registrant was
	Y	es X No	
	e the number of shares outstan as of the latest practicable d		s classes of common
	Stock, \$.10 par value	14,10	8,714 Shares
	Class	Outstanding a	t February 29, 2000

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

INDEX

	Page No.
PART I. FINANCIAL INFORMATION	
Item 1. Financial Statements	
Consolidated Condensed Statements of Income - Three Months Ended January 31, 2000 and 1999	3
Consolidated Condensed Balance Sheets - January 31, 2000 and October 31, 1999	l 4
Consolidated Condensed Statements of Cash Flows Three Months Ended January 31, 2000 and 1999	5
Consolidated Condensed Statements of Comprehensive Income Three Months Ended January 31, 2000 and 1999	6
Notes to Consolidated Condensed Financial Statements	7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	14
PART II. OTHER INFORMATION	
Item 6. Exhibits and Reports on Form 8-K	22
Signature	23
Index of Exhibits	24

PART I. FINANCIAL INFORMATION Item 1. Financial Statements THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Statements of Income (In thousands, except for earnings per share) (Unaudited)

Three Months Ended January 31,

	2000	1999
Net sales Cost of sales	\$40,404 13,772	\$34,959 13,416
Gross profit Selling, general and administrative expense Research and development expense Amortization of intangibles	26,632 16,764 648 980	21,543 14,222 461 957
Income from operations Interest expense Other income, net	8,240 1,381 400	5,903 1,849 34
Income from continuing operations before income taxes Provision for income taxes	7,259 2,432	4,088 1,447
Income from continuing operations Discontinued operations	4,827 	2,641 1,258
Income before cumulative effect of change in accounting principles Cumulative effect of change in accounting principles	4,827 (432)	3,899
Net income	\$ 4,395 ======	\$ 3,899 ======
Earnings per share: Basic and Diluted: Continuing operations Discontinued operations Cumulative effect of change in accounting principle	\$ 0.34 (0.03)	\$ 0.18 0.09
Earnings per share	\$ 0.31 ======	\$ 0.27 ======
Number of shares used to compute earnings per share: Basic	14,069 ======	14,427 ======
Diluted	14,359 ======	14,668 ======

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Balance Sheets (Unaudited)

	January 31, 2000	October 31, 1999
ASSETS	(In thou	
Current assets: Cash and cash equivalents Trade receivables, net Inventories Deferred tax asset Other current assets Total current assets Property, plant and equipment, net Goodwill and other intangibles, net Deferred tax asset Other assets	\$ 2,682 28,513 40,208 14,301 6,970 92,674 42,211 95,056 52,414 7,579 \$289,934	\$ 20,922 26,792 33,430 11,638 7,679 100,461 40,319 80,518 56,519 8,056 \$285,873
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities: Accounts and notes payable Current portion of long-term debt Accrued income taxes Other current liabilities Total current liabilities Long-term debt Other noncurrent liabilities	\$ 9,182 2,500 11,991 20,841 44,514 57,455 19,642	\$ 8,846 2,305 11,351 19,394 41,896 57,067 22,767
Total liabilities	121,611	121,730
Contingencies (Note 9) Stockholders' equity: Common stock, \$.10 par value Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Other Less, treasury stock at cost	1,502 251,843 (988) (69,930) (44) (14,060)	1,497 251,345 (595) (74,044) (14,060)
Total stockholders' equity	168,323	164,143
	\$289, 934 ======	\$285,873 ======

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Statements of Cash Flows (In thousands) (Unaudited)

Three Months Ended January 31, 2000 1999 ----------Net cash provided (used) by operating activities \$ 5,309 \$ (3,430) -----Cash flows from investing activities: Sale of securities 5,419 Disposition of discontinued operation, net of (costs) (89) 1,705 Purchases of property, plant and equipment (3,290)(2, 186)Acquisitions of assets and businesses (21,637)(71) Net cash provided (used) by investing activities (25,016) 4,867 Cash flows from financing activities: Repayments of long-term debt (18, 241)(6,659)Proceeds from long-term debt 19,500 2,218 (281) Dividends on common stock 456 0ther 1,493 Net cash provided (used) by financing activities (2,948) 1,434 Effect of exchange rate changes on cash and cash equivalents 33 (48) -----(1,559) Net decrease in cash and cash equivalents (18, 240)Cash and cash equivalents - beginning of period 7,333 20,922 Cash and cash equivalents - end of period \$ 2,682 \$ 5,774

=======

=======

THE COOPER COMPANIES, INC. AND SUBSIDIARIES Consolidated Condensed Statements of Comprehensive Income (In thousands) (Unaudited)

	Three Months Ended January 31,	
	2000	1999
Net income Other comprehensive income (loss):	\$4,395	\$3,899
Foreign currency translation adjustment	(393)	(79)
Comprehensive income	\$4,002 =====	\$3,820 =====

Note 1. General

The Cooper Companies, Inc. ("Cooper" or "we" and similar pronouns), through its principal subsidiaries, develops, manufactures and markets healthcare products. CooperVision ("CVI") markets a range of contact lenses to correct visual defects, specializing in toric lenses that correct astigmatism. Its leading products are disposable-planned replacement toric and spherical lenses. CVI also markets conventional toric and spherical lenses and lenses for patients with more complex vision disorders. CooperSurgical ("CSI") markets diagnostic products, surgical instruments and accessories to the women's healthcare market.

During interim periods, we follow the accounting policies described in our most recent Form 10-K. Please refer to this and to our Annual Report to Stockholders for the fiscal year ended October 31, 1999, when reviewing this Form 10-Q. The results in this report do not necessarily indicate future results.

The unaudited consolidated condensed financial statements presented in this report contain all adjustments necessary to present fairly Cooper's consolidated financial position as of January 31, 2000 and October 31, 1999, and the consolidated results of its operations and its consolidated cash flows for the three months ended January 31, 2000 and 1999. Adjustments consist only of normal recurring items except for an adjustment recorded in the first quarter of 2000, when we adopted statement of position ("SOP") 98-5, "Reporting on the Cost of Start-up Activities." (See Note 4.)

Note 2. Inventories, at the Lower of Average Cost or Market

	January 31, 2000	October 31, 1999
	(In thousa	ands)
Raw materials Work-in-process Finished goods	\$10,078 4,717 25,413	\$ 8,151 3,786 21,493
	\$40,208 ======	\$33,430 ======

Amounts recorded for January 31, 2000 include approximately \$4.9 million of inventories of companies acquired in the first quarter.

Note 3. Acquisitions

BEI ACQUISITION: On December 8, 1999, Cooper purchased a group of women's healthcare products from BEI Medical Systems Company, Inc. ("BEI") for approximately \$10.5 million in cash. The payment was made from cash then on hand. The products generate annual revenue of about \$8 million.

The acquired products include well-known brands of uterine manipulators and other products for the gynecological surgery market. Physicians use these products both in their offices and in hospitals. The majority of them are disposable.

The acquisition has been accounted for as a purchase. Excess of purchase price over net assets acquired (goodwill) has initially been recorded at \$8.2 million (pending completion of the allocation of the purchase price) and is being amortized over 20 years.

LEISEGANG ACQUISITION: On January 31, 2000, Cooper purchased a group of women's healthcare products and certain businesses (the "Leisegang Business") from NetOptix Corporation for approximately \$10 million in cash and an additional amount of approximately \$500,000 to be paid in the near future. The Leisegang Business currently generates annual revenue in excess of \$11 million and includes operations in the U.S., Germany and Canada.

Leisegang markets diagnostic and surgical instruments including colposcopes, instruments to perform loop electrosurgical excision procedures, hand-held gynecological instruments, disposable specula and cryosurgical systems. Many of its products are disposable, including its Sani-Spec line of disposable plastic specula, its largest product group.

The acquisition has been accounted for as a purchase. Goodwill has initially been recorded at \$6.7 million (pending completion of the allocation of the purchase price) and is being amortized over 20 years.

Note 4. Change in Accounting Principles

In April 1998, The American Institute of Certified Public Accountants issued SOP 98-5, "Reporting on the Cost of Start-up Activities." The SOP broadly defines start-up activities and requires companies to expense them as incurred, effective for fiscal years beginning after December 15, 1998. Cooper has, as required, adopted the SOP in the first quarter of fiscal year 2000 and reported an after tax charge of \$432,000 as a cumulative effect of a change in accounting principles. Our previous policy had been to defer start-up activities as appropriate and amortize them over 12 months on a straight line basis.

Note 5. Long-Term Debt

	January 31, 2000	October 31, 1999
	(In thousands)	
Promissory notes - Aspect Midland Bank KeyBank line of credit Aspect Vision bank loans Promissory note - Wesley-Jessen Corporation County of Monroe Industrial Development Agency ("COMIDA") Bond Capitalized leases	\$23,015 - 19,500 6,044 - 2,635 8,761	\$23,439 17,445 - 6,292 100 2,695 9,401
Less current installments	59,955 2,500 \$57,455	59,372 2,305 \$57,067

MIDLAND BANK

Cooper repaid the Midland Bank loan using cash then on hand and \$12.5 million of its KeyBank line of credit. Since the Midland Bank loan was guaranteed with a letter of credit against the KeyBank line of credit, at that time, we were able to reduce overall interest expense and increase the amount available under the KeyBank line of credit.

KEYBANK LINE OF CREDIT

At January 31, 2000, we had \$23.3 million available under the KeyBank line of credit.

PROMISSORY NOTE - WESLEY-JESSEN CORPORATION

The balance of the Wesley-Jessen promissory note was paid off in the first quarter.

Note 6. Earnings Per Share ("EPS")

	Three Months Ended January 31,	
	2000	1999
	(In thousands earnings pe	, except for
Income from continuing operations Discontinued operations Cumulative effect of change in accounting principles	\$ 4,827 (432)	1 259
Net income		\$ 3,899
Basic: Weighted average common shares	14,069 ======	14,427
Basic earnings per share:		
Continuing operations Discontinued operations Cumulative effect of change in accounting principles	\$ 0.34 (0.03)	\$ 0.18 0.09
Basic earnings per share	\$ 0.31 ======	
Diluted: Weighted average common shares	14,069	14,427
Add dilutive securities: Warrants Options	 290	38 203
Denominator for diluted earnings per share	14,359 ======	
Diluted earnings per share: Continuing operations Discontinued operations Cumulative effect of change in accounting principles	(0.03)	\$ 0.18 0.09
Diluted earnings per share	\$ 0.31 ======	\$ 0.27

We excluded the following options to purchase Cooper's common stock from the computation of diluted EPS because their exercise prices were above the average market price.

Three Months Ended January 31,

		•
	2000	1999
Number of shares excluded	798, 250 =======	1,177,500 =======
Range of exercise prices	\$30.69 - \$62.21 =========	\$23.44 - \$62.21 =========

Note 7. Income Taxes

The effective tax rate ("ETR") used to record the provision for income taxes of \$2.4 million for the three months ended January 31, 2000 was 33.5%. The ETR for the three-month period ended January 31, 1999 was 35.4%. The decrease in Cooper's ETR resulted from the August 1999 implementation of a new global corporate structure that increased our foreign income that is taxed at lower rates.

Note 8. Discontinued Operations

In the fourth quarter of 1998, Cooper declared Hospital Group of America ("HGA"), its psychiatric services business, a discontinued operation and recorded a charge of \$22.3 million reflecting Management's initial estimate of the ultimate loss to be incurred upon disposition.

In January 1999, Cooper completed the sale of a portion of HGA for \$5 million in cash and trade receivables. First quarter 1999 results include a credit of \$1.3 million, reflecting an adjustment to the estimated loss on the sale of this facility. We sold the remainder of HGA to Universal Health Services, Inc. for \$27 million at closing in 1999's fiscal second quarter.

HGA's patient revenue was \$12 million for the three months ended January 31, 1999.

Note 9. Contingencies -- Environmental

In 1997, environmental consultants engaged by Cooper identified a contained area of groundwater contamination consisting of industrial solvents including trichloroethane (also known as TCA) at one of CVI's sites. In the opinion of counsel, the solvents were released into the ground before we acquired the business at that site, and the area containing these chemicals is limited.

In April 1999, Cooper and the New York Department of Environmental Conservation entered into a voluntary agreement covering the environmental investigation of the site. The investigation has been completed, and we plan to begin a state-approved remediation later this year. Cooper has accrued approximately \$400,000 for that purpose. In the opinion of Management, the cost of remediation will not be material when considering amounts previously accrued.

Note 10. Cash Dividends

In fiscal 1999, Cooper announced that it intends to pay an annual cash dividend on its common stock of 8 cents per share, payable in quarterly installments of 2 cents per share. The dividend payment in our first fiscal quarter of 2000 was made on January 5, 2000.

Note 11. Business Segment Information

Cooper is organized by product line for management reporting with operating income, as presented in our financial reports, being the primary measure of the segment profitability. No costs from corporate functions are allocated to the segments' operating income. Items below operating income are not considered when measuring the profitability of a segment. The accounting policies used to generate segment results are the same as our overall accounting policies.

Identifiable assets are those assets used in continuing operations exclusive of cash and cash equivalents, which are included as corporate assets.

	Three Months Ended January 31,	
	2000	1999
Segment information (in thousands): Revenue:		
CVI CSI	\$ 31,969 8,435	\$ 27,779 7,180
	\$ 40,404 =======	\$ 34,959 =======
Operating income:		
CVI CSI Corporate	\$ 8,332 1,417 (1,509)	\$ 6,220 849 (1,166)
Total operating income Interest expense Other income, net	8,240 (1,381) 400	5,903 (1,849) 34
Income from continuing operations before income taxes	\$ 7,259 =======	\$ 4,088 ======

	January 31, 2000 	October 31, 1999
Identifiable assets (in thousands):		
CVI	\$155,535	\$153,759
CSI	64,219	41,491
Corporate	70,180	90,623
Total	\$289,934	\$285,873
	======	=======
	Three Mon Janua	ths Ended ry 31,
	2000	1999
Geographic information (in thousands): Revenue:		
United States	\$ 29,596	\$ 23,730
Europe	7,974	8,945
Canada	2,834	2,284
	\$ 40,404	\$ 34,959
	======	======
	January 31, 2000	October 31, 1999
Identifiable assets (in thousands): United States	\$100.060	¢ 06 267
Europe	\$109,969 93,604	\$ 86,367 92,025
Canada	8,305	4,434
Corporate and Other	78,056	103,047
Total	 \$289,934	\$285,873
	======	======

Note 12. Subsequent Event

On February 29, 2000, Cooper announced that it intends to pay its quarterly cash dividend of 2 cents per share on April 5, 2000 to stockholders of record on March 15, 2000.

Note numbers refer to "Notes to Consolidated Condensed Financial Statements" beginning on page 7 of this report.

FORWARD-LOOKING STATEMENTS: This Form 10-Q contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 including statements about Cooper's capital resources, anticipated revenue growth, operating results and market conditions. Since the outcome of forward-looking statements is uncertain, risky and, indeed, may not occur, investors should not rely on them to predict the future.

To identify forward-looking statements, look for words like "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Discussions of strategy, plans or intentions often contain forward-looking statements. These, and all forward-looking statements, necessarily depend on assumptions, data or methods that may be incorrect or imprecise.

Events, among others, that could cause actual results and future actions to differ materially from those described by or contemplated in the forward-looking statements include major changes in business conditions and the economy, loss of key senior management, major disruptions in the operations of Cooper's manufacturing facilities, new competitors or technologies, the impact of an undetected virus on our computer systems, acquisition integration costs, foreign currency exchange exposure, investments in research and development and other start-up projects, dilution to earnings per share from acquisitions or issuing stock, regulatory issues, significant environmental cleanup costs above those already accrued, litigation costs, costs of business divestitures, and other factors described in Cooper's Securities and Exchange Commission filings, including the "Business" section in our Annual Report on Form 10-K for the year ended October 31, 1999.

Cooper cautions investors not to rely unduly on forward-looking statements. They reflect our analysis only on their stated date.

RESULTS OF OPERATIONS

In this section we discuss the results of our operations for the first quarter of fiscal 2000 and compare them with those of 1999's first quarter. We discuss our cash flows and current financial condition beginning on page 20 in the "Capital Resources and Liquidity" section.

FIRST QUARTER HIGHLIGHTS

Sales up 16% to \$40.4 million.

Gross profit improved to 66% of sales from 62%.

Income from operations up 40% to \$8.2 million.

Diluted earnings per share from continuing operations up 89% to 34 cents from 18 cents.

SELECTED STATISTICAL INFORMATION - PERCENTAGE OF SALES AND GROWTH

	Percent of Sales Three Months Ended January 31,		
	2000	1999	% Growth
Net sales	100%	100%	16%
Cost of sales	34%	38%	3%
Gross profit	66%	62%	24%
Selling, general and administrative	41%	41%	18%
Research and development	2%	1%	41%
Amortization	2%	3%	2%
Income from operations	20%	17%	40%

NET SALES: All of Cooper's revenue is generated by our two business units, CooperVision ("CVI") and CooperSurgical ("CSI"):

 $\ensuremath{\mathsf{CVI}}$ markets a broad range of contact lenses primarily in North America and Europe.

 ${\tt CSI}$ markets diagnostic products, surgical instruments and accessories to the women's healthcare market primarily in the United States.

Our consolidated revenue grew \$5.4 million:

CVI CSI

Three	Month	ıs	Ended
Jar	nuary	31	.,

Janua	11 y 51,	0,4
		%
2000	1999	Increase
(Ir	n millions)	
\$32.0	\$27.8	15%
8.4	7.2	17%
\$40.4	\$35.0	16%
=====	=====	

CVI REVENUE: CVI's worldwide core business, which we define as all revenue except our lower margin original equipment manufacturer ("OEM") sales to other contact lens manufacturers, grew 18%:

Segment	First Quarter 2000	% Total	% Change from First Quarter 1999
	(\$ in millions)		
U.S. International	\$20.2 10.5	63% 33%	26% 5%
Core Business OEM	30.7 1.3	96% 4%	18% (28%)
Total	\$32.0 =====	100% ====	15%

CVI's core product sales in the U.S. grew 26% in the first quarter, as the disposable-planned replacement ("DPR") sphere and toric product lines together grew 42%.

U.S. toric lens business grew 28% in the first fiscal quarter while the toric market was growing about 5%. During the first fiscal quarter, sales of CVI's DPR torics grew 36% in the U.S., driven by sales of Preference Toric and Frequency 55 Toric together.

Sales of spherical DPR products in the U.S., driven by sales of Frequency 55 spheres, grew about \$1.7 million, or 56%.

During the first quarter, CVI continued to introduce Frequency Aspheric in the U.S. The optical properties of this lens help improve visual acuity in low light situations and correct low degrees of astigmatism without the need for a toric lens

CVI also recently introduced Encore, its cast-molded toric lens that will compete in the disposable (two-week) toric segment.

International core revenue, sales in countries outside the United States plus exports from the U.S., grew 5% during the quarter. Sales of lower-margin lenses to other contact lens manufacturers declined as expected, down 28% from last year's first quarter.

During the first quarter, the roll out of new products continued in Europe. These include CVI's line of toric lenses, the Frequency Aspheric lens and Frequency 55 UV, which contains an ultra violet light-blocking agent. In November, CVI introduced its cast-molded toric product--called Frequency XCEL--in Europe. XCEL is now available in every major European market except France, where we anticipate an April introduction.

CSI REVENUE: Revenue at CSI grew 17% over the comparable 1999 quarter to $\$8.4\ \mathrm{million}$.

In December, CSI acquired well-known brands of uterine manipulators and other niche products for the gynecologist's office from BEI Medical Systems Company, Inc.

At the end of January, CSI completed the acquisition of the Leisegang Business (See Note 4). The products are diagnostic and surgical instruments including colposcopes, instruments to perform loop electrosurgical excision procedures, hand-held gynecological instruments, disposable specula and cryosurgical systems. Many products are disposable, including the Sani-Spec line of disposable plastic specula, which comprises its largest product group.

COST OF SALES/GROSS PROFIT: Gross profit as a percentage of sales ("margin") was as follows:

	First Quar	First Quarter Margin	
	 2000	1999	
		1999	
CVI	69%	63%	
CSI	56%	55%	
Consolidated	66%	62%	

The gross profit improvement at CVI reflects cost reduction projects at both our U.S. and U.K. manufacturing sites. We believe that continued cost reductions will result in improving margins during the remainder of fiscal 2000 and beyond, aside from any major changes in product mix.

CSI's margins improved over the first quarter of fiscal 1999, primarily reflecting continued manufacturing efficiencies associated with Marlow and Unimar products. As the products recently acquired from BEI and Leisegang generate relatively lower margins, we anticipate that our overall margins at CSI will be about 53% of sales for the full fiscal year.

SELLING, GENERAL AND ADMINISTRATIVE ("SGA") EXPENSE:

Three Months Ended January 31,

		,			
		2000		1999)
			(\$ in millio	 ns)	
		% Rev.		% Rev.	% Increase
CVI	\$12.7	40%	\$10.6	38%	19%
CSI	2.6	31%	2.4	34%	6%
Headquarters	1.5	N/A	1.2	N/A	29%
	\$16.8	41%	\$14.2	41%	18%
	======		======		

As a percentage of sales, SGA was flat vs. 1999's first quarter. CVI's 19% increase in SGA was driven by marketing costs associated with new product launches. CSI SGA grew by 6%, with revenues growing 17%. The lower increase in SGA as related to sales growth is attributable to synergies with the acquisition of BEI products. Corporate SGA grew by \$300,000 in the first quarter of fiscal 2000 vs. the 1999 period. We expect that SGA growth at Headquarters will be about 10% for the full fiscal year.

RESEARCH AND DEVELOPMENT ("R&D") EXPENSE: We expect that R&D spending will remain at a low percentage of sales because we are focusing on acquiring products that will not require large expenditures of time or money before introduction.

INCOME FROM OPERATIONS: Operating income improved by \$2.3 million or 40% in the fiscal first quarter.

Three Months Ended January 31,

	200	0		1999	
		(\$	in millions)		
		% Rev.		% Rev.	% Increase
CVI CSI Headquarters	\$ 8.3 1.4 (1.5)	26% 17% N/A	\$ 6.2 0.9 (1.2)	22% 12% N/A	34% 67% N/A
	\$ 8.2 ======	20%	\$ 5.9 ======	17%	40%

INTEREST EXPENSE: Interest expense in the first quarter of 2000 of \$1.4 million was down 25% from 1999's first quarter, primarily reflecting debt payments we made at the end of the second quarter of 1999 with proceeds from the sale of HGA. (See "Risk Management.")

OTHER INCOME, NET: The primary components of other income are:

	Three Months Ended January 31,	
	2000	1999
	(In the	ousands)
Interest income Foreign exchange	\$211 (101)	\$ 51 (140)
Gain on cancellation of interest rate swap	240	- · · · · · · · · · · · · · · · · · · ·
Other	50	123
	\$400	\$ 34
	====	=====

PROVISION FOR INCOME TAXES: We estimate that our effective tax rate ("ETR") for the full fiscal year 2000 will be 33.5%. The effective tax rate in the first quarter of fiscal 1999 was 35.4%.

We implemented a global tax plan in the fourth quarter of fiscal 1999 to minimize both the taxes reported in our statement of income and the actual taxes we will have to pay once the benefits of our net operating loss ("NOLs") are fully utilized. Assuming no major acquisitions or large stock issuances, we currently expect to reduce our ETR to approximately 30% over the next six years. This plan could possibly extend the cash flow benefits of the NOLs through 2003. We expect that actual cash payments of taxes will be about 10% of pretax profits throughout this period.

GAIN ON DISPOSAL OF DISCONTINUED OPERATIONS: In January 1999, we completed the sale of a portion of our discontinued operation, Hospital Group of America, Inc. ("HGA"), for \$5 million in cash and trade receivables, and recorded a gain of \$1.3 million. We sold the remainder of HGA to Universal Health Services, Inc. for \$27 million at closing in April. (See Note 8.)

CUMULATIVE CHANGE IN ACCOUNTING PRINCIPLES: In the first quarter of 2000, we recorded a net of tax charge of \$432,000 to implement a new accounting principle. (See Note 4.)

CAPITAL RESOURCES & LIQUIDITY

FIRST QUARTER HIGHLIGHTS:

Operating cash flow positive \$5.3 million vs. negative \$3.4 million in 1999's first quarter.

Cash flow (pretax income from continuing operations plus depreciation and amortization) per diluted share 65 cents vs. 40 cents in 1999's first quarter.

Closed two acquisitions for cash payments of \$21.6 million.

Refinanced approximately \$18 million long-term debt, replacing it with less expensive debt under our Revolving Credit Agreement.

COMPARATIVE STATISTICS (DOLLARS IN MILLIONS, EXCEPT PER SHARE AMOUNTS):

	January 31, 2000	0000001 31, 133
Cash and cash equivalents	\$2.7	\$20.9
Total assets	\$289.9	\$285.9
Total debt	\$62.6	\$62.0
Ratio of debt to equity	0.4:1	0.4:1
Debt as a percentage of total capitalization	27%	27%
Operating cash flow - twelve months ended	\$36.4	\$27.7
Cash flow per diluted share - twelve months ended	\$3.08	\$2.82

January 31 2000 October 31 1000

OPERATING CASH FLOWS: Our major source of liquidity is cash flow provided by operating activities, which totaled \$5.3 million in the first quarter of fiscal 2000 and \$36.4 million over the twelve-month period ended January 31, 2000. Until this year, we had typically experienced a net cash outflow from operating activities in our first quarter, due to payments made to settle disputes, inventory builds in anticipation of new product launches and increased sales in subsequent quarters and bonus payments. In this year's first quarter, strong operating results that helped to decrease our net inventory build (of the total increase in inventory from October 31, 1999 of \$6.8 million, approximately \$4.9 million represented inventories of companies acquired in the first quarter) drove the positive cash flow performance. Major uses of cash for operating activities in the first quarter included payments of \$3 million related to settlements of disputes, \$1.4 million to fund entitlements under Cooper's bonus plans and \$900,000 in interest payments.

INVESTING CASH FLOWS: The cash outflow of \$25 million from investing activities was driven by capital expenditures of \$3.3 million and \$21.6 million in total to acquire BEI and Leisegang. (See note 3.)

FINANCING CASH FLOWS: Financing activities provided \$1.4 million in positive cash flows. In the quarter, we spent about \$18 million to refinance a portion of the debt raised to fund the acquisition of Aspect in December 1997. We funded this by drawing down on our KeyBank line of credit, which carries a lower effective interest rate. Because the debt we paid off was backed by a letter of credit from KeyBank, and was, therefore, deducted from our total facility amount, we lost no availability under our line of credit by effecting this transaction.

OUTLOOK: We believe that cash on hand of \$2.7 million plus cash from operating activities will fund future operations, capital expenditures, cash dividends (see Note 10) and smaller acquisitions. We may need additional funds for larger acquisitions and other strategic alliances. At January 31, 2000, we had over \$23 million available under the KeyBank line of credit and anticipate that additional financing would be available as required.

RISK MANAGEMENT: Cooper is exposed to risks caused by changes in foreign exchange, principally Pound Sterling denominated debt and from operations in foreign currencies. We have hedged most of the debt by entering into contracts to buy Sterling forward. Cooper is also exposed to risks associated with changes in interest rates, as the interest rate on certain of its debt varies with the London Interbank Offered Rate.

YEAR 2000 ("Y2K"): In 1999, we completed an in-depth compliance program to minimize the effect of potential Y2K issues. To date, we have experienced no difficulties related to Y2K.

TRADEMARKS: The following trademarks italicized in this report are owned by, licensed to or distributed by The Cooper Companies, Inc., its subsidiaries or affiliates: Cerveillance'r', FemExam'r' TestCard System'TM', Hyskon'r', Marlow'TM', Frequency 55'r', Preference'r', Frequency'r' Aspheric, Encore'TM', Frequency'r' XCEL, Sani-Spec'r' and Unimar'r'.

PART II - OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits.

27

Exhibit Number	Description
11*	Calculation of Earnings Per Share

* The information called for in this exhibit is provided in Footnote 6 to the Consolidated Condensed Financial Statements in this report.

Financial Data Schedule.

(b) Cooper filed the following reports on Form 8-K during the period from November 1, 1999 to January 31, 2000.

Date of Report Item Reported

December 8, 1999 Item 5. Other Events January 31, 2000 Item 5. Other Events

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	The Cooper Companies, Inc.
	(Registrant)
Date: March 10, 2000	/s/ Stephen C. Whiteford
	Vice President and Corporate Controller
	23
STATE	EMENT OF DIFFERENCES
	pressed as'TM'

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Index of Exhibits

Exhibit No.		Page No.
11*	Calculation of Earnings Per Share.	
27	Financial Data Schedule.	

* The information called for in this exhibit is provided in Footnote 6 to the Consolidated Condensed Financial Statements in this report.

1,000

```
3-M0S
       OCT-31-2000
            )V-01-1999
JAN-31-2000
2,682
          NOV-01-1999
                      0
                29,943
1,430
                  40,208
              57,005
14,794
289 00
             92,674
             289,934
        44,514
                      57,455
                      1,502
             0
                       0
                  166,821
289,934
                      40,404
               13,772
13,772
400
             40,404
            0
1,381
               7,259
                 2,432
           4,827
                   0
                  0
(432)
4,395
                   .31
```